10x Genomics (TXG) Cost of Revenue (2018 - 2026)

10x Genomics has disclosed Cost of Revenue across 9 years of filings, most recently posting $44.7 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $44.7 million, down 9.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $194.2 million (down 1.76% YoY), and the FY2025 annual result was $198.9 million, up 1.34% from the prior year.
• Cost of Revenue came in at $44.7 million for Q1 2026 at 10x Genomics, down from $53.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $68.2 million in Q4 2023 to a low of $25.5 million in Q1 2022.
• The 5-year median for Cost of Revenue is $47.8 million (2025), against an average of $45.3 million.
• Across the five-year window, Cost of Revenue soared 463.66% in 2022 and retreated 22.12% in 2024, its largest moves.
• 10x Genomics' Cost of Revenue stood at $36.8 million in 2022, then soared by 85.18% to $68.2 million in 2023, then slipped by 20.72% to $54.1 million in 2024, then retreated by 2.0% to $53.0 million in 2025, then dropped by 15.7% to $44.7 million in 2026.
• The last three Cost of Revenue figures came in at $44.7 million (Q1 2026), $53.0 million (Q4 2025), and $48.7 million (Q3 2025), per Business Quant data.